RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 166 filers reported holding RIGEL PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,013 | -16.4% | 22,234 | -0.1% | 0.00% | – |
| Q2 2023 | $28,711 | +7.1% | 22,257 | +9.6% | 0.00% | – |
| Q1 2023 | $26,809 | -19.5% | 20,310 | -8.5% | 0.00% | – |
| Q4 2022 | $33,308 | -16.7% | 22,205 | -33.8% | 0.00% | – |
| Q3 2022 | $40,000 | +8.1% | 33,559 | +2.4% | 0.00% | – |
| Q2 2022 | $37,000 | -75.2% | 32,785 | -34.1% | 0.00% | – |
| Q1 2022 | $149,000 | -8.6% | 49,731 | -19.0% | 0.00% | – |
| Q4 2021 | $163,000 | -23.1% | 61,409 | +5.2% | 0.00% | -100.0% |
| Q3 2021 | $212,000 | -34.8% | 58,391 | -22.0% | 0.00% | 0.0% |
| Q2 2021 | $325,000 | +38.3% | 74,901 | +9.0% | 0.00% | 0.0% |
| Q1 2021 | $235,000 | +5.4% | 68,731 | +7.9% | 0.00% | 0.0% |
| Q4 2020 | $223,000 | +93.9% | 63,727 | +32.6% | 0.00% | 0.0% |
| Q3 2020 | $115,000 | +25.0% | 48,055 | -3.9% | 0.00% | – |
| Q2 2020 | $92,000 | +80.4% | 50,028 | +52.0% | 0.00% | – |
| Q1 2020 | $51,000 | -59.5% | 32,907 | -44.3% | 0.00% | -100.0% |
| Q4 2019 | $126,000 | +4.1% | 59,051 | -8.5% | 0.00% | 0.0% |
| Q3 2019 | $121,000 | -30.5% | 64,534 | -3.1% | 0.00% | 0.0% |
| Q2 2019 | $174,000 | -9.8% | 66,579 | -11.3% | 0.00% | 0.0% |
| Q1 2019 | $193,000 | +12.9% | 75,042 | +1.2% | 0.00% | 0.0% |
| Q4 2018 | $171,000 | -39.8% | 74,174 | -16.1% | 0.00% | -50.0% |
| Q3 2018 | $284,000 | +10.9% | 88,413 | -2.3% | 0.00% | 0.0% |
| Q2 2018 | $256,000 | -16.6% | 90,478 | +4.4% | 0.00% | 0.0% |
| Q1 2018 | $307,000 | -21.5% | 86,639 | -14.1% | 0.00% | -33.3% |
| Q4 2017 | $391,000 | +95.5% | 100,879 | +28.2% | 0.00% | +50.0% |
| Q3 2017 | $200,000 | -0.5% | 78,697 | +6.7% | 0.00% | 0.0% |
| Q2 2017 | $201,000 | -23.6% | 73,769 | -7.2% | 0.00% | -33.3% |
| Q1 2017 | $263,000 | +35.6% | 79,452 | -2.4% | 0.00% | +50.0% |
| Q4 2016 | $194,000 | -23.0% | 81,423 | +18.5% | 0.00% | -50.0% |
| Q3 2016 | $252,000 | +41.6% | 68,728 | -14.1% | 0.00% | +100.0% |
| Q2 2016 | $178,000 | +12.7% | 79,983 | +5.5% | 0.00% | 0.0% |
| Q1 2016 | $158,000 | -38.0% | 75,842 | -9.7% | 0.00% | -33.3% |
| Q4 2015 | $255,000 | +608.3% | 84,022 | +655.4% | 0.00% | – |
| Q2 2015 | $36,000 | -40.0% | 11,123 | -34.2% | 0.00% | -100.0% |
| Q1 2015 | $60,000 | +42.9% | 16,911 | -8.2% | 0.00% | – |
| Q4 2014 | $42,000 | -72.7% | 18,424 | -76.9% | 0.00% | -100.0% |
| Q3 2014 | $154,000 | -55.5% | 79,607 | -16.4% | 0.00% | -50.0% |
| Q2 2014 | $346,000 | -42.5% | 95,280 | -38.6% | 0.00% | -50.0% |
| Q1 2014 | $602,000 | +370.3% | 155,074 | +244.0% | 0.01% | +300.0% |
| Q4 2013 | $128,000 | -58.4% | 45,076 | -47.6% | 0.00% | -71.4% |
| Q3 2013 | $308,000 | +27.8% | 86,053 | +19.5% | 0.01% | +40.0% |
| Q2 2013 | $241,000 | – | 72,034 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
| Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
| ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
| GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
| NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
| Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.03% |
| XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |